Sinocelltech Group (SHA:688520) will conduct clinical trials on its SCTV02 injection after obtaining approval from the Chinese drug regulator, the National Medical Products Administration.
The pharmaceutical trials will test the drug as a treatment used to prevent respiratory diseases caused by the respiratory syncytial virus, according to a Shanghai Stock Exchange disclosure on Wednesday.
The company's shares jumped 3% in recent trade.
Price (RMB): ¥41.21, Change: ¥+1.2, Percent Change: +3.03%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.